Kornimate/medical-research-clean huggingface dataset:
embryonal tumors of infancy & childhood: south egypt cancer institute experience

Conditions: Neoplasms, Embryonal; Embryonal Neoplasms

Summary: the aim of this study is to investigate demographic \& disease characteristics of pediatric cancer patients diagnosed with one of embryonal tumors to identify the prevalence, the spectrum of these disease entities \& treatment outcomes in these patients.

background: embryonal tumors arise from cells that are normally present in the developing embryo and originate in developing tissues and organ systems. these tumors occur almost exclusively in children, and are usually diagnosed in children before age 5 years. the group is heterogeneous and includes relatively common pediatric tumors as well as rare tumors. three common types of embryonal tumors in children are neuroblastoma, wilms tumor (wt), and retinoblastoma. other embryonal tumors, include medulloblastoma and rhabdomyosarcoma. patients \& methods: from january 2001 to december 2015, retrieval \& analysis of the medical records of pediatric patients with embryonal tumors will be made at the pediatric oncology department, south egypt cancer institute which represents the largest referral center in upper egypt. these data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.

Eligibility criteria:
inclusion criteria: * patients whose age less than or equal to 18 years. * patients diagnosed with any of embryonal neoplasms. exclusion criteria: • patients whose age more than 18 years.

Keywords: childhood cancer pediatric oncology embryonal neoplasms embryonic neoplasms embryonic tumors embryonal tumors
the effect of music in the pediatric emergency department waiting room on caregiver anxiety

Conditions: Anxiety

Summary: the purpose of this research study is to examine the effects of playing classical music in the waiting room on caregiver anxiety. people who enter the study will be asked a few identifier questions including age and relation to patient and then will be asked fill out a survey regarding anxiety.

the study investigators will initially screen for participants based on the patient's acuity level. if the patient meets the low acuity requirement and if they have a wait time greater than 20 minutes then the caregiver will be approached to obtain informed consent once they have been placed in a room. if they choose to be included in the study, the patient's medical record number will be recorded, a personal identification number will be assigned, and the patient's information will be entered into the personal identification number key and into our research database. a questionnaire asking participants age and relation to patient and the state-trait anxiety inventory will be administered to the caregiver. an additional question of perceived wait time will also be asked.

Eligibility criteria:
inclusion criteria: * adult caregivers; age \>18 year, accompanying a pediatric patient with acuity level ≥ 4 * patient must have been in waiting area for at least 20 minutes exclusion criteria: * non-english speaking caregivers * hearing impaired caregivers * caregivers accompanying a patient with an acuity level less than 4

Keywords: music emergency caregivers
rehabilitation of finger flexor tendon injuries

Conditions: Flexor Tendon Rupture

Summary: the primary objective is to compare the two different rehabilitation protocols relative motion flexion and short splint regarding patients'satisfaction in patients with flexor tendon injuries in zone i and ii after 13 and 26 weeks post-surgery.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * ≥ 18 years old * understanding of the german language (written and oral) * single and multiple finger injuries * primary flexor tendon injuries in zone i-v for the fingers and/ or thumb * treated by the hand surgery department at the inselspital bern * treated with at least a 4-strand core suture exclusion criteria: * \< 18 years old * inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients * replantation of the injured finger * fracture of the injured finger * primary tendon reconstructions
phase 2 study to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis


Eligibility criteria:
inclusion criteria: * physician diagnosis of atopic dermatitis for greater than (\>) 1 year * atopic dermatitis involvement of greater than or equal to (\>=) 10 percent (%) body surface area * easi score of \>= 12 * scorad of \>= 25 * iga score of \>= 3 * effective birth control in line with protocol details exclusion criteria: * history of anaphylaxis following any biologic therapy * hepatitis b, c or human immunodeficiency virus * pregnant or breastfeeding * history of cancer * previous receipt of tralokinumab
gallbladder volvulus diagnosed intraoperatively: case report

Conditions: Gallbladder Volvulus

Summary: 85-year-old female patient presented with right upper quadrant pain of one day duration, diagnosed with acalculous cholecystitis, and intraoperatively diagnosed with gallbladder volvulus.

85-year-old female patient presented with right upper quadrant pain of one day duration that is associated with nausea and vomiting, but no fever or jaundice. she was tachycardiac and had severe abdominal right upper quadrant tenderness with positive murphy's sign. laboratory results showed only increase in inflammatory markers. both ultrasound and computed tomography scan of the abdomen were done and acalculous cholecystitis was diagnosed. open cholecystectomy was done but gallbladder volvulus was noted intraoperatively. cholecystectomy was done and the patient had smooth postoperative recovery.

Eligibility criteria:
inclusion criteria: * any patient presenting with right upper quadrant pain exclusion criteria: * patients having non gallbladder related pathologies explaining right upper quadrant pain

Keywords: gallbladder volvulus acalculous cholecystitis
obstructive sleep apnea syndrome: evaluation of the efficacy of sleepinnov© (spiri+) continuous positive airway pressure device

Conditions: Obstructive Sleep Apnea Syndrome

Summary: continuous positive airway pressure (cpap) is the reference treatment of patients suffering from obstructive sleep apnea syndrome (osas).this device functions as a pneumatic stent that stabilizes the upper airway, prevents periodic collapses during sleep.the correction of abnormal respiratory events during sleep allows improvement of symptoms related to osas and restores quality of life.the purpose of this study is to validate the efficacy of a new cpap brand developed by sleepinnov©.

obstructive sleep apnea syndrome (osas) is characterized by the repetitive occurrence of partial or complete pharyngeal obstructions during sleep.continuous positive airway pressure (cpap) is the first line treatment of osas. the aim of the prospective monocentric two steps pilot study spiri+ is to validate the efficacy of a new cpap brand developed by sleepinnov©. * the first step will validate the capability of the algorithm to appropriately detect of abnormal repiratory events during sleep.the metrics will be a comparison of the total number of events detected by the cpap sleepinnov© with data arising from a concurrent polysomnography. * the second step will check overall clinical efficacy of the new cpap device by assessing the percentage of osas with an index of residual events below 10 and 5 per hour.

Eligibility criteria:
inclusion criteria: * newly diagnosed and untreated obstructive sleep apnea syndrome (iah \>15/hour) with an indication of treatment with cpap * patients who have given their informed written consent exclusion criteria: * pregnant or lactating women * patients not affiliated to the french social security system or equivalent * patient deprived of liberty by judicial or administrative decision * patients under guardianship or curatorship

Keywords: continuous positive airway pressure
fistulotomy versus fistulotomy with marsupialization

Conditions: Fistula in Ano

Summary: it was a study comparing two standard procedures for fistula in ano

it was a study which compared two standard surgical procedures for fistula in ano

Eligibility criteria:
inclusion criteria: * having low lying anal fistula willing to enroll in study exclusion criteria: * unfit pts having uncontrolled diabetes
hepatic effects of gastric bypass surgery

Conditions: Liver Diseases

Summary: liver disease in the morbidly obese is thought to occur due to the long-term presence of fat deposits in the liver, resulting in inflammation and scarring of the liver over time, which reduces liver function. however, many of these patients are unaware that their liver is damaged. there is currently no consensus regarding what the long-term effects of gastric bypass surgery are on pre-existing liver disease in morbidly obese patients. this study will determine the long-term effects on the liver after this type of surgical procedure.

before or on the day of surgery liver function will be determined using the ddg-2001 analyzer. this monitor is able to detect the concentration of a dye called indocyanine green dye (icg) when present in the blood stream. a dose of 0.5 mg/kg of icg will be injected into an iv in the arm. over approximately fifteen minutes the ddg-2001 analyzer will determine how quickly the liver removes the dye icg from the blood stream. this value represents how well the liver is functioning. blood samples are drawn before injection of icg to measure liver function using standard liver function tests. this same routine for injecting icg and obtaining blood for routine liver function tests will happen one more time, after surgery, once the subject has lost a significant amount of the original weight (60% of excess weight). this amount of weight loss typically occurs between 12 to 18 months after gastric bypass surgery. this second icg measurement will occur during an outpatient follow-up visit to ccf. a biopsy will be taken from the liver during surgery. a second biopsy taken after the 60% weight loss will be compared to determine the effect of this surgery on the liver.

Eligibility criteria:
inclusion criteria: 1. bmi \> 40. 2. documented failed non-surgical treatment for morbid obesity. 3. ability to undergo long-term follow-up after lgbs. exclusion criteria: 1. bmi \< 40. 2. subject age \< 18 years. 3. inability to undergo long-term follow-up after lgbs (living distance \> 300 miles). 4. patients with known esld. 5. patients found to have evidence of esld during preoperative evaluation for lgbs including portal hypertension, ascites, and coagulopathy. 6. patients with known iodine sensitivity or allergy.

Keywords: gastric bypass surgery hepatic disease hepatic function
microneedle patch for psoriatic plaques

Conditions: Psoriasis; Administration, Topical

Summary: the purpose of this study is to evaluate the efficacy of microneedle patch on the psoriatic plaques.

as a novel minimally invasive approach, microneedle-mediated transdermal drug delivery has received increased attention. microneedle patch effectively penetrates the skin barrier of the stratum corneum and create efficient pathways for the delivery of drugs. a randomized controlled trial based on split-body was planned to evaluate the efficacy of enhanced transdermal delivery of topical agent by hyaluronic acid (ha)-fabricated microneedle patch in psoriatic plaques. six psoriatic plaques in a patient will be randomized to either microneedle ha patch, patch, or control groups. patch group is planned for rule out the occlusion effect of patches. all lesions will be treated with topical agent and patches daily for 2-week period. the severity of psoriasis will be grated with modified pasi score and the clinical improvement will be assessed as % from baseline every week. overall 20 patients with 120 psoriatic plaques will be enrolled.

Eligibility criteria:
inclusion criteria: * age: older than 19 * a patient with psoriasis * a patient with symmetrical psoriatic lesions * a patient with the willingness to comply with the study protocol during the study period and capable of complying with it * a patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages exclusion criteria: * age: lower than 20 * a pregnant or lactating patient * a patient who cannot understand the study or who does not sign the informed consent

Keywords: psoriasis
efficacy of natural ingredient to improve the swallowing response of patients with oropharyngeal dysphagia

Conditions: Dysphagia

Summary: assessment of the improvement of the safety of the swallowing function under 3 natural ingredients known to be agonist of sensory receptors.

the trial will be double-blind, randomized, monocentric, and interventional with a hybrid design. the subjects will be randomized to one of the three parallel active ingredient groups. products will be compared versus control (thicken up clear - nectar viscosity), which adds a part of cross over within the design. the total sample size is 84 enrolled subjects. patients will be males and females aged 55+ with mild proven dysphagia.

Eligibility criteria:
inclusion criteria: * patients aged 55+ * patients showing impaired safety of the deglutition during the v-vst (volume - viscosity swallow test): cough oxygen desaturation ≥3% or voice change. * neurodegenerative or ischemic/hemorrhagic cerebral cause (stroke) or elderly subjects exclusion criteria: * patients radiated for treatment of head and neck cancer idiosyncrasis * allergy to food or medication, especially contrast products (iodine) * major respiratory disease needing oxygen as standard treatment. * any major and relevant abdominal, head and neck, or chest surgery within the three months preceding the study. * have a high alcohol consumption (more than 2 drinks/day) * subject who cannot be expected to comply with the study procedures, including consuming the test products. * currently participating or having participated in another clinical trial during the month preceding the study * patients with relevant mucosal damage or with in-mouth irritation * patients with pacemaker or electrode implants * epileptic patients
pattern of skin manifestations in chronic hepatitis c virus patients before and after direct acting anti viral drugs

Conditions: Hepatitis C, Chronic

Summary: * hepatitis c is an infectious disease caused by the hepatitis c virus (hcv) that primarily affects the liver. it is one of the main causes of chronic liver diseases worldwide . * according to world health organization (who), 2011 , egypt has particularly high rates of hepatitis c (22%). * hepatitis c virus (hcv) is known to induce both hepatic and extra-hepatic manifestations. about 17% of hcv patients present with at least one skin manifestation, which can be directly or indirectly induced by chronic hcv infection .

* skin diseases which are certainly related with chronic hcv infection are mixed cryoglobulinemia, lichen planus , porphyria cutanea tarda, chronic pruritus and necrolytic acral erythema; conditions that may share a possible association with hcv infection . * while several immune-mediated inflammatory skin conditions, such as psoriasis, chronic urticaria and vitiligo, have been only rarely reported in the setting of chronic hcv infection . * peginterferon based regimen with or without ribavirin were the mainstay of hcv treatment with a cure rate of about 50%, although these regimens were lengthy, complex, had significant side-effects and high failure rates . * they also had higher rate of exacerbated dermatologic conditions such as discoid lupus, psoriasis and lichen planus . * recently, newer all-oral anti viral drugs regimens began to be approved for use in 2014. these regimens, involve one pill daily for 12 weeks, they have achieved sustained virologic response of over 90% and have more tolerable side effect profiles. * recently, the european association for study of liver (easl) 2015, american association for the study of liver diseases (aasld) and infectious diseases society of america (idsa) have now recommended that all chronically infected hcv patient should be offered treatment with new oral antiviral drugs .

Eligibility criteria:
inclusion criteria: 1. patients with hcv infection eligible for treatment with new (daads) and having: a- normal complete blood count ( hemoglobin not less than 10 gm/dl ). b- mild to moderate impairment of liver function test and kidney function test. c- positive polymerase chain reaction for hcv virus. d- controlled blood sugar . 2. patients \> 18 years exclusion criteria: 1. patients on treatment for skin disease. 2. pregnancy and lactation. 3. patients \<18 years. 4. patients not eligible for oral anti hepatitis c drugs.

Keywords: skin manifestations - hepatitis c virus
clinical validation of a fractional administration device for holmium-166 sirt

Conditions: Liver Cancer; Liver Metastasis Colon Cancer; Primary Liver Cancer

Summary: to investigate the in vivo performance and safety of a novel medical device for the injection of holmium-166 microspheres during radioembolization. the main potential advantage of this device is that it allows for injection of a during treatment determined dose, which is not possible with the current administration tool.


Eligibility criteria:
inclusion criteria: 1. diagnosis of hepatocellular carcinoma or liver metastases originating from colorectal cancer. 2. at least one lesion of ≥10 mm in the longest diameter on contrast-enhanced mri or contrast-enhanced ct 3. patient is eligible for sirt as determined by the tumour board (in dutch: mdo) 4. patient has a life expectancy of 12 weeks or longer 5. patient has a who performance score of 0-2 exclusion criteria: 1. significant extrahepatic disease (2x sum of diameters of lesions outside the liver \> sum of lesions inside the liver) 2. radiation therapy, chemotherapy or major surgery within 4 weeks before treatment 3. serum bilirubin \> 2.0 x the upper limit of normal 4. alat, asat, alkaline phosphatase (af) \> 5x the upper limit of normal 5. glomerular filtration rate (gfr-mdrd) \<35 ml/min 6. leukocytes \<4.0 \* 109/l or platelet count \<60 \* 109/l 7. significant heart disease that in the opinion of the physician increases the risk of ventricular arrhythmia. 8. pregnancy or breast feeding 9. disease with increased chance of liver toxicity, such as primary biliary cirrhosis or xeroderma pigmentosum 10. patients ineligible to undergo mr-imaging (claustrophobia, metal implants, etc) 11. portal vein thrombosis of the main branch (more distal branches are allowed) 12. evidence of clinically relevant, untreated grade 3 portal hypertension 13. untreated, active hepatitis 14. body weight \> 150 kg (because of maximum table load) 15. severe allergy for i.v. contrast (iomeron, dotarem and/or primovist) 16. lung shunt \> 30 gy, as calculated using scout dose holmium-166 spect/ct 17. uncorrectable extrahepatic deposition of scout dose activity. activity in the falciform ligament, portal lymph nodes or gallbladder are accepted.
a prospective, open label comparison of ezetimibe, niacin, and colestipol as adjunct therapy in lipid reduction

Conditions: Hyperlipidemia; Hypercholesterolemia

Summary: to compare ldl reduction compared to baseline in patients using maximum tolerated hmg coa reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. the patient's cardiovascular risks are assessed to determine if national cholesterol education program's adult treatment panel iii (ncep atp iii) guidelines for low density lipoprotein (ldl) reduction were achieved between the three groups. secondary measures examine the safety issues with liver function test (lft) monitoring and rhabdomyolysis. high-density lipoproteins (hdl) elevations are monitored between the three groups to determine efficacy as a secondary outcome.

: patients with hyperlipidemia who sign consent and who are currently at maximum tolerated dose of a statin and are not meeting ncep atpiii treatment goals for ldl cholesterol are enrolled in 12-week open label, prospective trial. patients are randomized into one of three groups to receive ezetimibe, niacin, or colestipol in addition to current statin therapy. patients are titrated as tolerated to therapeutic doses of study medications (ezetimibe 10mg/day, niacin 1500mg/day, and colestipol 20gm/day). at baseline, informed consent; a laboratory admission profile (chem20); weight; height; blood pressure; concomitant medications; cholesterol medication history; and grapefruit juice consumption data are gathered. at weeks 6 and 12, patients have their cholesterol panels and liver function tests assessed. patients are also interviewed regarding side effects (including rhabdomyolysis), tolerance, changes in concomitant medications, and grapefruit juice consumption, along with weight and blood pressure measurements.

Eligibility criteria:
inclusion criteria: * veterans eligible for treatment at the tuscaloosa va medical center * 50 years of age * male or female * any race or ethnic group * signed informed consent * hyperlipidemia despite current maximum tolerated dose of an hmg coa reductase inhibitor (statin) for \> 6 weeks * currently not meeting ncep atpiii treatment goals for ldl cholesterol exclusion criteria: * known hypersensitivity or intolerance to ezetimibe, niacin, or colestipol * previous failed adequate trial of adjunctive ezetimibe, niacin, or colestipol * consumes more than 8oz. grapefruit juice daily * significant medical condition that would impact safety evaluations (i.e. significantly elevated lft, hepatitis, severe dermatitis, uncontrolled diabetes, severe gi disease, fibromyalgia, renal failure, recent cva or mi, pancreatitis, etc.) * receiving medications that would be contraindicated to use in combination with ezetimibe, niacin, or colestipol

Keywords: ezetimibe niacin colestipol hyperlipidemia adjunct therapy zetia